FLGT Fulgent Genetics, Inc.

CIK 0001674930 40 ready 8-Ks latest July 30, 2026, 4:09 PM ET RSS · JSON

Activity: QUIET 0 filings / 30d vs 1 baseline

Ready 8-Ks 40

Latest filing July 30, 2026, 4:09 PM ET

Top materiality 0.90

Event mix earnings ×20 · other_material ×9 · m_and_a ×4

Sentiment 16 pos · 2 neg · 22 neu

Executive change recent →

Recent 8-K filings for FLGT

Highest-materiality recent filing

Fulgent Genetics Q2 revenue $153.6M (+790% YoY); acquires CSI Labs, invests in Helio Health and FF Gene Biotech

August 9, 2021, 7:59 PM ET earnings materiality 0.90 positive item 2.02 item 7.01 item 9.01

Q2 revenue $153.6M (+790% YoY); ~1.6M billable tests (9x YoY); gross margin improved ~21pp YoY.
GAAP net income $79.8M ($2.59 EPS); non-GAAP net income $78.7M ($2.55 EPS); adjusted EBITDA $105.0M.

Read filing →

July 30, 2026, 4:09 PM ET earnings materiality 0.75 neutral item 2.02 item 7.01 item 9.01

Fulgent Genetics Q2 2026 revenue $85.4M, GAAP loss $1.05/share, revises FY revenue guidance to $330-340M

Revenue of $85.4M, up 20.1% sequentially; GAAP gross margin 30.1%.
June 1, 2026, 7:07 PM ET other material materiality 0.65 positive item 8.01 item 9.01

Fulgent Genetics reports encouraging Phase 2 data for FID-007 in HNSCC at ASCO 2026

FID-007 + cetuximab showed 61.9% objective response rate in PD-1 resistant R/M HNSCC.
May 21, 2026, 5:04 PM ET other material materiality 0.60 positive item 8.01 item 9.01

Fulgent reports FID-007 + cetuximab Phase 2 HNSCC data: 60% ORR, 7.2 mo mPFS

Interim Phase 2 data: ORR 60% (58% Arm A, 61% Arm B); mPFS 7.2 months across 42 evaluable patients.
May 14, 2026, 4:27 PM ET other material materiality 0.55 neutral item 5.02 item 5.07 item 9.01 ◈ Shareholder Votes ×4

Fulgent Genetics shareholders approve 2026 equity plan authorizing 2M new shares

2026 Equity Incentive Plan replaces prior 2016 plan; authorizes 2,000,000 new shares plus up to 1,500,000 from forfeited awards.
May 1, 2026, 7:59 PM ET earnings materiality 0.70 negative item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Fulgent Q1 2026: GAAP EPS -$0.80, revenue $71.1M, reiterates FY2026 guidance

GAAP net loss of $24.8M ($0.80/share); non-GAAP loss of $11.0M ($0.36/share).
March 17, 2026, 7:59 PM ET M&A materiality 0.70 neutral item 1.01 item 2.01 item 7.01 item 9.01 ◈ M&A Transactions ×2

Fulgent Genetics completes acquisitions of Bako Diagnostics and StrataDx for ~$56.9M cash

Total combined purchase price approximately $56.9 million in cash, subject to post-closing adjustments.
February 27, 2026, 6:59 PM ET earnings materiality 0.75 neutral item 2.02 item 7.01 item 9.01

Fulgent Genetics Q4 2025 revenue $83.3M (+9% YoY); GAAP loss $0.76/share, Non-GAAP income $0.16/share

Q4 2025 revenue of $83.3M, up 9% year-over-year; full-year revenue $322.7M, up 14%.
December 22, 2025, 6:59 PM ET M&A materiality 0.70 positive item 1.01 item 8.01 item 9.01 ◈ Material Agreements ×2

Fulgent Genetics to acquire Bako Diagnostics and StrataDx for $55.5M total

Acquires equity of StrataDx for $12.5M cash; asset purchase from Bako entities for $43.0M cash.
November 7, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

Fulgent Genetics Q3 revenue $84.1M (+17% YoY), raises FY guidance, non-GAAP EPS $0.14

Revenue $84.1M, up 17% YoY; raised full-year 2025 revenue guidance to $325.0M.
October 20, 2025, 7:59 PM ET other material materiality 0.65 positive item 8.01 item 9.01

Fulgent reports Phase 2 FID-007 combo data: 51% ORR, PFS 7.8 months in R/M HNSCC

Preliminary Phase 2 data for FID-007 + cetuximab in 1L-2L R/M HNSCC; 39 patients randomized.
August 1, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 7.01 item 9.01

Fulgent Q2 core revenue $81.7M (+16% YoY); raises FY2025 guidance to $320M

Core revenue $81.7M, up 16% YoY; total revenue $81.8M.
May 15, 2025, 7:59 PM ET other material materiality 0.15 neutral item 5.07

Fulgent Genetics elects directors, ratifies auditor, approves say-on-pay at 2025 meeting

All four director nominees elected: Ming Hsieh (19.3M for), Michael Nohaile (16.0M for), Regina Groves (14.3M for), Linda Marsh (13.8M for).
May 2, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 7.01 item 9.01

Fulgent Q1 core revenue $73.5M (+16% YoY); GAAP loss $0.37/share; reiterates FY25 guidance

Core revenue of $73.5M, up 16% YoY; GAAP net loss of $11.5M ($0.37 loss per share).
February 28, 2025, 6:59 PM ET earnings materiality 0.70 neutral item 2.02 item 7.01 item 9.01

Fulgent Genetics reports Q4 2024 core revenue up 14% YoY to $76.0M; full year core revenue up 7% to $281.2M

Full year total revenue $283.5M; core revenue (ex-COVID) grew 7% to $281.2M.
November 8, 2024, 6:59 PM ET earnings materiality 0.65 neutral item 2.02 item 7.01 item 9.01

Fulgent Q3 core rev $71.7M (+9% YoY), GAAP loss $0.48, non-GAAP EPS $0.31; guides FY core rev $280M

Total revenue $71.7M, core revenue (ex-COVID) $71.7M, up 9% YoY.
August 2, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 7.01 item 9.01

Fulgent Q2 core revenue $70.2M (+5% YoY); GAAP loss $0.29/share improves EPS guidance

Total revenue $71.0M; core revenue $70.2M (+5% YoY).
May 16, 2024, 7:59 PM ET other material materiality 0.10 neutral item 5.07 ◈ Shareholder Votes ×3

Fulgent Genetics announces 2024 annual meeting voting results

All four director nominees elected: Ming Hsieh, Michael Nohaile, Regina Groves, Linda Marsh (votes for ranged ~15.8M to 20.0M).
May 3, 2024, 7:59 PM ET earnings materiality 0.50 neutral item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Fulgent Q1 2024 core revenue $63.2M (+1% YoY), GAAP loss $0.45/share, reiterates FY guidance

Total revenue $64.5M; core revenue $63.2M (+1% YoY); FY2024 core revenue guidance reiterated at $280M.
February 28, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Fulgent Genetics reports Q4 GAAP loss $128.1M; core revenue grows 21% YoY

Full year total revenue $289.2M; core revenue (ex-COVID) grew 44% to $262.1M.
November 3, 2023, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Fulgent reports Q3 total revenue $85M, core revenue up 17% to $66M, GAAP loss $0.44/share

Core revenue (ex-COVID) grew 17% YoY to $66M; total revenue $85M including $19M from COVID reimbursements.
August 4, 2023, 7:59 PM ET earnings materiality 0.65 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Fulgent Genetics Q2 core revenue rises 48% to $67M; raises FY2023 guidance to $260M

Total revenue $68M; core revenue $67M, up 48% YoY.
May 18, 2023, 7:59 PM ET other material materiality 0.45 neutral item 5.02 item 5.07 item 9.01 ◈ Shareholder Votes ×4

Fulgent Genetics stockholders approve 3M share increase to 2016 Incentive Plan

Stockholders elected all four director nominees: Ming Hsieh, Michael Nohaile, Regina Groves, Linda Marsh.
May 5, 2023, 7:59 PM ET earnings materiality 0.65 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Fulgent Q1 core revenue rises 150% to $62.7M; raises FY2023 core revenue guidance to $250M

Total revenue $66.2M; core revenue (ex-COVID) $62.7M, up 150% YoY, a record.
February 28, 2023, 6:59 PM ET earnings materiality 0.70 neutral item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Fulgent Genetics Q4 2022 GAAP loss $0.80/share; core revenue up 97% YoY to $55M

Q4 total revenue $67.7M; core revenue (ex-COVID) $55.0M, up 97% YoY.
January 12, 2023, 6:59 PM ET other materiality 0.20 neutral item 1.01 item 9.01 ◈ Material Agreements

Fulgent Genetics extends HQ lease by one year at $24,885/month

Lease amendment extends headquarters lease from Jan 31, 2023 to Jan 31, 2024.
January 3, 2023, 6:59 PM ET leadership materiality 0.35 positive item 5.02 item 8.01 item 9.01 ◈ executive_change

Fulgent Genetics appoints Reggie Groves to board, cures Nasdaq audit committee deficiency

Reggie Groves appointed to Fulgent Board effective Jan 3, 2023; serves on Audit, Compensation, and Nominating/Governance committees.
November 23, 2022, 6:59 PM ET regulatory materiality 0.50 negative item 3.01 ◈ Listing & Compliance Notices

Fulgent Genetics receives Nasdaq non-compliance letter for audit committee shortage; cure period to Oct 2023

Received Nasdaq letter Nov 18, 2022: audit committee has 2 independent directors instead of required 3.
November 7, 2022, 6:59 PM ET other material materiality 0.80 neutral item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Fulgent Genetics Q3 core revenue up 110% to $56M; acquires Fulgent Pharma for ~$100M

Q3 revenue $105.7M (down 54% YoY due to COVID decline); GAAP EPS $0.06, non-GAAP EPS $0.32.
November 4, 2022, 7:59 PM ET leadership materiality 0.40 neutral item 5.02 ◈ executive_change

Director Leonard Post Resigns from Fulgent Genetics Board

Leonard Post resigned as director and as Chair of the Nominating and Corporate Governance Committee on October 31, 2022.
September 29, 2022, 7:59 PM ET leadership materiality 0.35 neutral item 5.02 ◈ executive_change

Director John Bolger resigns from Fulgent Genetics board effective Sept 24, 2022

John Bolger resigned as director and Audit Committee Chair on Sept 24, 2022.
August 4, 2022, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 7.01 item 9.01

Fulgent Genetics Q2 revenue $125.3M; core revenue up 102% YoY, guidance raised

Total revenue $125.3M (Q2 2021: $153.6M); billable tests 1.3M (vs 1.6M).
June 30, 2022, 7:59 PM ET leadership materiality 0.40 neutral item 5.02 ◈ executive_change

Director Yun Yen resigns from Fulgent Genetics board and committees effective June 25, 2022

Dr. Yen resigned from the Board, Audit, Compensation, and Nominating & Corporate Governance Committees.
May 19, 2022, 7:59 PM ET other materiality 0.15 neutral item 5.07

Fulgent Genetics holds 2022 annual meeting; all director nominees and proposals approved

All four director nominees elected: Hsieh 15.9M for, Bolger 10.6M (5.6M withheld), Yen 12.3M, Marsh 12.9M.
May 3, 2022, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 7.01 item 9.01

Fulgent Genetics Q1 revenue $320.3M, core revenue up 59%, raises FY outlook to $660M

Revenue $320.3M (down from $359.4M Q1 2021); GAAP net income $154M ($4.93/share).
April 26, 2022, 7:59 PM ET M&A materiality 0.75 neutral item 2.01 item 9.01

Fulgent Genetics completes $170M acquisition of Symphony Buyer via merger

Total purchase price of approximately $170 million, subject to customary adjustments for closing cash, indebtedness, working capital, and expenses.
April 18, 2022, 7:59 PM ET M&A materiality 0.80 positive item 1.01 item 2.02 item 9.01

Fulgent Genetics to acquire Inform Diagnostics for $170M; prelim Q1 revenue ~$300M, above guidance

Acquisition of Inform Diagnostics for ~$170M cash; expected to close Q2 2022, funded from cash on hand.
March 29, 2022, 7:59 PM ET other material materiality 0.35 neutral item 5.02 item 9.01

Fulgent Genetics adopts executive clawback policy for incentive compensation misconduct

Policy applies to Section 16 officers; covers equity awards and cash incentives granted on/after March 28, 2022.
February 23, 2022, 6:59 PM ET earnings materiality 0.80 positive item 2.02 item 7.01 item 9.01

Fulgent Genetics Q4 revenue $251.7M, full year 2021 revenue $992.6M, core revenue up 236% YoY

Q4 revenue $251.7M; full year 2021 revenue $992.6M, up 135% year-over-year.
November 9, 2021, 6:59 PM ET earnings materiality 0.85 positive item 2.02 item 7.01 item 9.01

Fulgent Genetics Q3 revenue $227.9M (+124% YoY); raises FY revenue guidance to $930M

Revenue $227.9M (+124% YoY); core revenue $40.1M (+292% YoY).
August 9, 2021, 7:59 PM ET earnings materiality 0.90 positive item 2.02 item 7.01 item 9.01

Fulgent Genetics Q2 revenue $153.6M (+790% YoY); acquires CSI Labs, invests in Helio Health and FF Gene Biotech

Q2 revenue $153.6M (+790% YoY); ~1.6M billable tests (9x YoY); gross margin improved ~21pp YoY.

Executive changes

Appointed

Regina Groves

Director

FLGT · Fulgent Genetics, Inc.

Effective: 2023-01-03
Filed: January 3, 2023, 6:59 PM ET

On January 3, 2023, the Board of Directors (the “Board”) of the Fulgent Genetics, Inc. (the “Company”) appointed Ms. Regina (“Reggie”) Groves to serve as a member of the Board.

Departed

Leonard Post

Director and Chair of the Nominating and Corporate Governance Committee

FLGT · Fulgent Genetics, Inc.

Effective: 2022-10-31
Filed: November 4, 2022, 7:59 PM ET

On October 31, 2022, Leonard Post notified the Board of Directors (the “Board”) of Fulgent Genetics, Inc. (the “Company”) of his decision to resign from the Board and as the Chair of the Nominating and Corporate Governance Committee of the Board effective as of October 31, 2022.

Departed

John Bolger

Director

FLGT · Fulgent Genetics, Inc.

Effective: 2022-09-24
Filed: September 29, 2022, 7:59 PM ET

On September 24, 2022, John Bolger notified the Board of Directors (the “Board”) of Fulgent Genetics, Inc. (the “Company”) of his decision to resign from the Board.

Departed

Yun Yen

Director

FLGT · Fulgent Genetics, Inc.

Effective: 2022-06-25
Filed: June 30, 2022, 7:59 PM ET

On June 25, 2022, Yun Yen, M.D., Ph.D., F.A.C.P., notified the Board of Directors (the “Board”) of Fulgent Genetics, Inc. (the “Company”) of his decision to resign from the Board, the Audit Committee, the Compensation Committee, and the Nominating and Corporate Governance Committee of the Board, effective as of June 25, 2022.

Materiality & sentiment trend

Max materiality 0.90 · Median 0.65 · Most common event earnings

16 positive 2 negative 22 neutral

source · FLGT on sec.gov